Oligometastasis

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)

Metastasis-directed Therapy for Oligometastases of Breast Cancer

stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients

SMC Radiation Oncology SABR Cohort for Oligometastasis

Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study

Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC